GlassScriptPhysician profile
Hunter C Townson
NPI 1336802479
$1,110.48
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,043 · 2023: $67.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $67.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $67.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $187.97 | 2022 | |
| Novartis Pharmaceuticals Corporation | $184.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.78 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $129.66 | 2022 | |
| Amgen INC. | $86.01 | 2022 | |
| Merck Sharp & Dohme LLC | $80.46 | 2022 | |
| Daiichi Sankyo INC. | $47.49 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.11 | 2022 | |
| Atricure, INC. | $38.81 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $37.57 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.95 | 2022 | |
| Csl Behring | $29.12 | 2023 | Kcentra |
| Pfizer INC. | $24.62 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.85 | 2022 | |
| Daxor Corporation | $11.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Townson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.